NEWS
Dr. David T. Rubin on the 100th Episode of Bowel Moments Podcast
Meet Dr. David T Rubin – EPISODE 100!
UChicago Medicine Patient First in the World to Receive Ulcerative Colitis Drug Since FDA Approval
A University of Chicago Medicine patient became the first person with ulcerative colitis in the world to receive the drug guselkumab (Tremfya) since its Sept. 11 approval by the FDA for treating moderate to severe ulcerative colitis. Tremfya has been used for many years to treat plaque psoriasis and psoriatic arthritis, but it was proven to also be an effective treatment for ulcerative colitis in a global study led by UChicago Medicine’s David T. Rubin, MD, Professor of Medicine and Chief of the Section of Gastroenterology, Hepatology and Nutrition. The study contributed to the FDA’s approval for its use for this disease.
Read more about this here on Newswise
Dr. David T. Rubin on “How I Treat Ulcerative Colitis”
Dr. Rubin provides an in-depth look at the treatment of ulcerative colitis, from recent advances in therapeutic agents to setting patient expectations, positioning treatments, and monitoring for disease remission or progression. Click here for the full talk from the Advances in IBD Network on the HMP Global website.
Dr. David T. Rubin on Transabdominal Ultrasound for IBD: Lessons from STARDUST Substudy on Ustekinumab
Intestinal ultrasound has become a useful tool in assessing disease progression and pathophysiology of inflammatory bowel disease (IBD). It’s an approach to visualizing the intestines using a transabdominal ultrasound probe to provide real-time information. But could research from the STARDUST substudy on ustekinumab provide new options for these patients? Tune in with Dr. Peter Buch for an in-depth conversation with Dr. David Rubin, Professor of Medicine at the University of Chicago Pritzker School of Medicine. Click here for the full talk from GI Insights on ReachMD’s website.
Dr. Noa Krugliak Cleveland Discusses Her Award-Winning Research on Decreasing Time to Treatment Change and Remission in IBD Patients
At this year’s ACG (American College of Gastroenterology) Conference in Vancouver, British Columbia, Canada, Dr. Noa Krugliak Cleveland gave an oral presentation on her award-winning abstract “Monitoring IBD by Intestinal Ultrasound Decreases Time to Treatment Change and Time to Remission in Comparison to Conventional Management.” Click here to further understand these added benefits of intestinal ultrasound.
IBD Drive Time Podcast: Ethical Issues in Clinical Trials
Take a listen to the third episode of a four-part series wherein Professor Rubin guest-hosts the Gastroenterology Learning Network’s IBD Drive Time and discusses the ethics of clinical trials in IBD, as well as challenges to recruitment, alongside Professor Severine Vermeire (KU Leuven, Belgium) and Professor Dan Turner (Hebrew University of Jerusalem, Israel).
Dr. David T. Rubin on Bowel Urgency: the Next Frontier in Management of Ulcerative Colitis
Listen here as Professor David T. Rubin discusses bowel urgency in ulcerative colitis and its management with Professor Laurent Peyrin-Biroulet in a recent episode of IBDscope.
Dr. David T. Rubin Guest-Hosts IBD Drive Time, Again!
In the second of a four-part series guest-hosting the Gastroenterology Learning Network’s IBD Drive Time, Dr. Rubin discusses the impact of the obstacles of the prior authorization process on patients and providers. Listen here, as he is joined by David Choi, specialty clinical pharmacist and associate director of the IBD center at UChicago, and Mona Shah, senior director of policy and strategy at Community Catalyst, a nonprofit organization that aims to ground healthcare policy and practice change goals within community.
Dr. David T. Rubin Guest-Hosts IBD Drive Time
Take a listen to Dr. Rubin discuss the impact of inflammatory bowel disease on sexual function with University of Chicago’s GI psychologist, Dr. Alyse Bedell, and pelvic floor physical therapist, Sarah Macaraeg.